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Factor VII-Vila, in association with tissue factor, 
participates in the complex which initiates blood co­
agulation through the extrinsic pathway. To identify 
functional domains on factor VII which mediate the 
activation of factor X, 16 synthetic peptides corre­
sponding to 55% of the primary structure were assayed 
for their ability to inhibit factor VII function. Factor 
Xa formation was inhibited by eight of the peptides in 
a dose-dependent manner. Kinetic analyses indicated 
noncompetitive inhibition of factor X activation by 
seven of these peptides. Peptide-(347—361) inhibited 
factor Xa cleavage of a chromogenic substrate by a 
competitive mechanism and was excluded from further 
analysis in this study. Among the seven inhibitory 
peptides which have the ability to prevent the factor 
VHa-tissue factor-mediated conversion of factor X to 
factor Xa, peptide-(285—305) was most inhibitory, 
with a K i  value of 2.4 ixM. The K t values were in the 
range of 42—65 mm for peptides-(44-50), -(194-214), 
-(208-229), and -(376—390). The least inhibitory pep­
tides were at positions 170—178 and 330—340, with a 
K i  value >200 fiM. Polyclonal antibodies were raised 
against four of these peptides; and when antisera were 
assayed by a solid-phase radioimmunoassay, they 
bound not only to their respective immunizing pep­
tides, but also to factor VII. The Fab fragments of 
specific IgG preparations, affinity-purified on a factor 
VH-agarose column, inhibited the rate of factor X ac­
tivation in a dose-dependent manner. Six of the seven 
inhibitory peptides represent amino acid sequences 
within the heavy chain of factor VII, and the remaining 
one corresponds to a sequence within the light chain. 
The corresponding regions in the x-ray crystal struc­
ture of chymotrypsin represented by the six heavy 
chain inhibitory peptides are found to be located in 
three distinct regions, one region located spatially dis­
tal to the active site and the other two regions located 
relatively closer to the active site and the substrate- 
binding pocket. The results suggest that at least three 
specific regions in the heavy chain and one region in 
the light chain of factor VII mediate its interaction 
with the factor X activation complex.
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Coagulation is initiated by the expression of tissue factor, 
a nonproteolytic integral membrane receptor/cofactor of fac­
tor VII, by either extravascular cells upon injury or vascular 
cells on stimulation by a variety of biological agonists (1 , 2). 
This factor VH-VIIa-tissue factor complex activates factor X 
to its active enzyme form (Xa), which leads to the formation 
of clots by the extrinsic pathway (1-3). In addition, this 
complex can activate factor IX to factor IXa and promote 
clotting by recruiting the intrinsic pathway (4).
Factor VII, a trace vitamin K-dependent serine protease 
zymogen, is synthesized and secreted as a single-chain mole­
cule consisting of 406 amino acid residues (5-7). The activa­
tion of factor VII to factor V ila involves the hydrolysis of a 
single peptide bond between Arg152 and lie163, the resulting 
two-chain molecule (Vila) consisting of a light chain of 152 
amino acid residues and a heavy chain of 254 amino acid 
residues held together by a single disulfide bond (7). The light 
chain of factor V ila contains the 10 7 -carboxylglutamic acid 
residues and two growth factor homology domains, whereas 
the heavy chain contains the catalytic domain typical of serine 
proteases. Factor VII, unlike other zymogen forms, can react 
with diisopropyl fluorophosphate, a potent inhibitor of serine 
proteases (6, 9). In addition, bovine factor VII exhibits ~ 1 -  
2% of the coagulant activity of factor V ila (5). This has led 
to the suggestion that factor VII is an “active zymogen.” 
However, recent studies (10, 11) provide evidence to show 
that human factor VII is a true zymogen and must be cleaved 
prior to the expression of proteolytic activity. The complex of 
factor VHa-tissue factor in the presence of Ca2+ on a phos­
pholipid membrane surface rapidly activates both factors X  
and IX (3, 4), whereas only a minimal amount of coagulant 
activity is observed in the absence of tissue factor (12). By in 
vitro experiments, a number of activated coagulation proteins 
including factors Xa (5), IXa (13), and X lla  (5, 13) and 
thrombin (9) have been shown to activate factor VII to factor 
Vila.
The primary structure of factor VII bears considerable 
sequence similarity to the family of vitamin K-dependent 
coagulation proteins (8). Furthermore, the catalytic domain 
of factor VII, like other members of the vitamin K-dependent 
proteins, shows a marked sequence and predicted structural 
homology to the pancreatic serine proteases trypsin and chy­
motrypsin (14-18). However, the presence of calcium, protein 
cofactors, and membrane surfaces is essential for the rapid 
activation of coagulation serine proteases; and most of them  
also exhibit a high degree of specificity for a limited number 
of plasma protein substrates. These specific interactions of 
vitamin K-dependent serine proteases must relate to the 
extended molecular recognition sites on their surface. These 
sites of molecular recognition may be derived from a contig­
uous sequence of amino acids or by a combination of discon­
tiguous sequences which are in close spatial proximity at the 
























Molecular interaction requires that the regions mediating 
these associations must be at the solvent-accessible surface 
of the molecule. We have used two approaches to examine the 
regions on factor VII which mediate assembly and function 
of the extrinsic pathway activation complex. Synthetic pep­
tides representing ~55% of the primary structure of factor 
VII and selected antipeptide antibodies were used to conclude 
that at least three specific regions on the heavy chain and one 
region on the light chain of factor VII mediate its interaction 
with the factor X  activation complex.
EXPERIM ENTAL PROCEDURES
Materials—Factors VH-VIIa (19), X (20), and Xa (21) were isolated 
as previously reported. Tissue factor was prepared from human brain 
as described earlier (22). t-Butoxycarbonyl-derivatives were obtained 
from Chemical Dynamics Corp. (South Plainfield, NJ) and Peninsula 
Laboratories, Inc. (Belmont, CA), and 9-fluorenylmethoxycarbonyl- 
derivatives were bought from Milligen/Biosearch (Bedford, MA), 
Calbiochem, or Peninsula Laboratories, Inc. Glutaraldehyde (25%), 
cyanogen bromide, keyhole limpet hemocyanin, and rabbit brain 
phospholipids (cephalin) were purchased from Sigma. Sepharose 4B 
and Sephadex G-25 were obtained from Pharmacia LKB Biotechnol­
ogy Inc. The chromogenic substrate for factor Xa, CBS 31.39 
(CH:!S04-D-Leu-Gly-Arg-p-nitroanilide-AcOH), was bought from 
American Byproducts Co. (Parsippany, NJ). Protein A-agarose, pa- 
pain-agarose, bicinchoninic acid protein reagent, m-maleimidoben- 
zoyl-iV-hydroxysulfosuccinimide ester, and IODO-GEN iodination 
reagent were obtained from Pierce Chemical Co. All other reagents 
were of the highest purity available.
Peptide Synthesis and Characterization—Peptides with amino acid 
sequences corresponding to the primary structure of factor VII, num ­
bered according to Hagen et al. (8), are listed in Table I. First- 
generation peptides were synthesized by the Merrifield solid-phase 
methodology as described by Glass (23). Synthesis was performed on 
a Biosearch SAM II synthesizer at the 1-meq scale. All the residues 
were double-coupled using a 3-fold molar excess of each f-butoxycar- 
bonyl-derivative to benzylhydrylamine resin. Deblocking was per­
formed with 30% trifluoroacetic acid in dichloromethane for 30 min. 
Peptides were cleaved from the resin, and side chain deprotection 
was achieved by treatm ent with anhydrous hydrofluoric acid (HF) 
containing 20% anisole for 45 min a t 0 °C. Peptides containing 
histidine were also treated with 2-mercaptoethanol before HF cleav­
age to remove the dinitrophenyl side chain protecting group. All the 
subsequent peptides were made manually in a RAMPs™ peptide 
synthesizer (Du Pont-New England Nuclear) using the 9-fluorenyl- 
methoxycarbonyl chemistry following the manufacturer’s protocols 
for synthesis and cleavage.
All the peptides were initially gel-filtered on a Bio-Rad P-2 column 
(2.5 X 83 cm) equilibrated in 1% acetic acid. Subsequent analysis and 
purification were performed on a Perkin-Elmer high pressure liquid 
chromatography system using a Vydac C4 column (2.1 X 25 cm, 5 /tm) 
equilibrated in 0.1 % trifluoroacetic acid and developed with a linear 
gradient of 0-50% acetonitrile over 50 min. The composition and 
concentration of isolated peptides were determined by subjecting 
them to 24-h hydrolysis in 6  N HC1 in evacuated tubes at 110 °C and 
by subsequent analysis on a Beckman Model 6300 amino acid ana­
lyzer.
Preparation, Characterization, and Purification o f Polyclonal A n ti­
peptide Antibodies—Antibodies were raised in rabbits against selected 
synthetic peptides coupled to keyhole limpet hemocyanin. One mg of 
m-maleimidobenzoyl-Af-hydroxysulfosuccinimide ester was dissolved 
in 15 /il of dimethylformamide and mixed with 5 mg of keyhole limpet 
hemocyanin previously dissolved in 1 ml of 20 mM phosphate, 150 
mM NaCl, pH 7.4 (PBS). After 30 min of incubation at ambient 
temperature, the low molecular weight reactants were separated from 
keyhole limpet hemocvanin/m-maleiinidobenzayl ;Y hydroxy sue 
cinimide ester by gel filtration using a Sephadex G-25 column (1 X 
18 cm) equilibrated in PBS. This protein was reacted with 5 mg of a 
cysteine-containing peptide for 3 h at room temperature. The peptide- 
carrier conjugates (300 /ig) in 150 /d of PBS were emulsified with an 
equal volume of Freund's complete adjuvant and injected intrader- 
mally into four sites, one over each limb. After 2 weeks, the conjugate 
was emuslified in Freund’s incomplete adjuvant and injected subcu­
taneously into four sites, one over each limb. The animals were 
challenged every month thereafter, and sera were collected weekly,
starting 6 weeks after the initial immunization.
Sera were tested for reactivity against factor VII and free peptides 
using a solid-phase radioimmunoassay as described previously (24). 
Purification of IgG from rabbit antisera was achieved by affinity 
chromatography on protein A-agarose (24). The concentration of IgG 
was determined by the bicinchoninic acid protein assay method using 
bovine serum albumin as standard. Specific antibodies were purified 
by passing the IgG fraction of each peptide antiserum over a 10-ml 
column of factor VII coupled to agarose (25) at a concentration of 0.5 
mg of factor VH/ml of agarose beads. The antibody bound to the 
column was eluted with 100 mM glycine HC1, pH 3.0; concentrated 
using Amicon PM -10 membranes; and dialyzed against PBS. For 
selected studies, monovalent Fab fragments were prepared by papain 
digestion of the specific antibody (24).
Rate o f Factor X  Activation—The effect of synthetic peptides on 
the rate of factor X activation was analyzed in a purified system 
employing a chromogenic assay (24). For inhibition experiments, 
peptides were diluted in 20 mM Tris-HCl, 150 mM NaCl, pH 7.4 
(TBS), and preincubated with 10 /ul each of factor X (12 nM) and 
tissue factor (0.075%) at 37 °C in a total volume of 140 /il, adjusted 
with TBS containing 1% bovine serum albumin and 5 mM CaCl2 
After 30 min, factor X activation was initiated by the addition of 10 
/il of factor VII (0.2 pM). At defined time intervals, 20-jul aliquots 
were removed and added to a  microtiter plate containing 80 /tl of 50 
mM Tris-HCl, 225 mM NaCl, and 10 mM EDTA, pH 8.2. Following 
sample collection, 50 /ul of 0.6 mM chromogenic substrate (CBS 31.39) 
was added, and the rate of change in the absorbance at 405 nm was 
monitored for 10 min using a Vmax kinetic microplate reader (Molec­
ular Devices, Palo Alto, CA). The rate of factor Xa formation was 
calculated from the slope of a linear regression of the data plotted as 
a function of the initial rate of hydrolysis (A^s/min) versus time and 
expressed as A^s/min2.
Coagulation Assays—The effect of synthetic peptides on factor VII 
coagulation activity was determined using a two-stage clotting assay 
as described earlier (24). Synthetic peptides were individually prein­
cubated with 20 n 1 each of plasma (immunochemically depleted of 
factor VII) and 0.25% tissue factor at 37 °C in a total volume of 180 
/d, adjusted with TBS containing 1 % bovine serum albumin. At the 
end of 30 min, coagulation was initiated by the addition of 10 /d each 
of 5 mM CaCl2 and factor VII (1 nM). The time for clot formation 
was measured using a Fibrometer (BBL Microbiology Systems, Cock- 
eysville, MD).
Inhibition Assays—The inhibition of factor VII function was de­
termined in the two-stage chromogenic assay described above. The 
peptides were initially screened at a 200 nM final concentration. To 
determine the concentration of peptide required to  inhibit the rate of 
factor X activation by 50% (CI50), peptides or antipeptide antibody 
Fab fragments at various concentrations, including buffer (TBS/ 
bovine serum albumin) controls, were incubated with their respective 
complexes. Following the addition of factor VII, the rate of factor Xa 
formation was determined, and the percent of the rate of factor X 
activation in the presence of different concentrations of factor VII 
peptides relative to buffer controls was calculated. Analogous deter­
minations of CI50 values were measured in the specific coagulation 
assay outlined above. Factor V ila activity in the presence of varying 
concentrations of peptide was quantitated by comparing the clotting 
times to a standard curve constructed from the log of the clot time 
versus the log of a known amount of factor VII in the same reaction 
mixture without added peptide.
RESULTS
The synthetic peptides representing the binding sites on 
factor VII and the native protein would be expected to com­
pete for interaction with the components of factor X  activa­
tion complex (the binding of factor VII to tissue factor or 
factor X  to the assembled enzyme complex) and prevent its 
activation. On the basis o f this rationale, the effect of these 
peptides on the rate of factor X  activation was analyzed in a 
purified protein system employing a chromogenic assay. To 
optimize the effect of the peptides, each of the components 
was titrated, and the concentration of enzyme (factor VII- 
Vlla) used was in excess relative to the cofactor (tissue factor). 
For inhibition experiments, the peptides were preincubated 
with factor X  and tissue factor at a concentration of 103-104­





















of 30 min was sufficient for the peptides to be in equilibrium 
with the target proteins, and the rates of factor X a formation 
were linear over the 8-min sampling period. The rates of 
factor Xa formation (Fig. 1) in the presence and absence of 
synthetic peptides were hyperbolic with respect to factor X  
(substrate) concentration. The rate of factor Xa formation in 
the presence of peptide-(285-305) was reduced by ~60%, but 
by <10% by peptide-(226-243). To further enhance the sen­
sitivity of detection of potential inhibitory peptides, the sub­
strate concentration was maintained at or below the K m of 
the reaction, and the enzyme (factor VII) concentration was 
made as low as practically possible.
The amino acid sequences of 16 synthetic peptides of factor 
VII and their effect on the rate of factor X  activation are 
depicted in Table I. Each of these peptides was preincubated 
individually at a final concentration of 200 with the 
components of the factor X  activation complex (factor X,
o
o
Factor X Concentration ( nM )
Fig. 1. Effect of selected synthetic peptides on rate of factor 
X a formation as function of concentration of factor X. A
mixture of tissue factor (0.05%), factor X (varying concentrations), 
and 5 mM CaCl2 was incubated with buffer (■), 248 fiM peptide-(226- 
246) (A), or 4.5 peptide-(285-305) (•) . The reaction was started 
by adding factor VH-VIIa to a final concentration of 0.2 pM. Aliquots 
were withdrawn at selected time points, and the rate of factor Xa 
formation was measured using a chromogenic assay as described 
under “Experimental Procedures.”
tissue factor, and Ca2+) before the addition of factor VII, and 
the rate of factor Xa formation was determined. Factor X 
activation was completely inhibited by six of the synthetic 
peptides: (peptides-(40-50), -(194-204), -(208-229), -(285­
305), -(347-361), and (376-390)), and partial inhibition was 
observed for two peptides (peptides-(170-178) and -(330­
340)). Peptides which reduced the rate of factor Xa formation 
by <25% were considered not significantly inhibitory at this 
high concentration. None of these inhibitory peptides, except 
peptide-(347-361), inhibited the amidolytic activity of factor 
Xa when they were directly incubated with factor Xa, sug­
gesting that only peptide-(347-361) is an active-site inhibitor 
of factor Xa and that the seven other inhibitory peptides have 
the ability to prevent the factor VH-mediated activation of 
factor X.
To determine the relative potency of these inhibitory pep­
tides in preventing the activation of factor X, each of them 
was incubated individually at varying concentrations with the 
components of the factor X  activation complex before the 
addition of factor VII, and the rate of factor Xa formation 
was measured relative to controls lacking the added peptides 
(Fig. 2). All of the seven inhibitory peptides tested showed a 
dose-dependent inhibition. However, the relative potency of 
peptides varied over a wide range. The concentration required 
for 50% inhibition (CI50) by peptide-(285-305) was 14-22-fold 
less than that for peptides-(44-50), -(194-214), -(206-229), 
and -(376-390) and 75-100-fold less than that for peptides- 
(170-178) and -(330-340). Table II lists the CI50 values meas­
ured for each peptide. Peptide-(285-305) was the most potent 
in inhibiting the activation of factor X, whereas peptides- 
(170-178) and -(330-340) were least effective. The decreasing 
order of their ability to prevent factor X activation was: 285­
305 >  208-229 >  44-50 >  376-390 >  194-214 >  170-178 >  
330-340.
To test whether the peptide inhibition of factor X  activation 
observed in a purified protein system could also be demon­
strated in a more complex coagulation assay, selected peptides 
were incubated individually with factor VH-deficient plasma, 
and clotting activity was determined following the addition of 
factor VII. The effect of varying concentrations of the three 
most inhibitory peptides on the clotting activity of factor VII
T a b le  I
Effect o f synthetic peptides representing prim ary structure of hum an factor V II 
on rate of factor X  activation
Peptide Amino acid sequence Factor Xa formation0
44-50 YSDGDQC
% of control rate 
0





208-229 + GC LGEHDLSEHDGDEQSRRVAQVI(GC) 0
226-243 + GC AQVIIPSTYVPGTTNHDI(GC) 86
246-262 LRLHQPVVLTDHVVPLC 83
262-279 CLPERTFSERTLAFVRFS NSk
285-305 + GC GQLLDRGATALELMVLNVPRL(GC) 0
303-329 PRLMTQDCLQQSRKVGDSPNITEYMFC 92
330-340 AGYSDGSKDSC 62
347-361 + GC PHATHYRGTWYLTGI(GC) 0‘
376-390 VYTRVSQYIEWLQKL 0
387-406 LQKLMRSEPRPGVLLRAPFP 98
° The rate of factor Xa formation was determined by an amidolytic assay using purified proteins at a 200 ,uM 
concentration of each of the synthetic peptides. Amino acid sequences are numbered according to the primary 
structure of human factor VII; G and C in parentheses are additional glycyl and cysteinyl residues. 
b NS, not soluble.























Fig. 2. Dose-dependent inhibition by factor V II synthetic 
peptides of rate o f factor X a formation initiated by factor VII- 
tissue factor complex. Tissue factor (0.075%) and factor X (12 nM) 
were combined in the presence of varying concentrations of the 
indicated peptides and incubated for 30 min at 37 °C. Factor VII (0.2 
pM) was added to initiate the reaction. At selected time points, 
aliquots were removed, and the factor Xa activity was measured. Data 
are plotted as percentage of the rate of factor Xa formation deter­
mined in the absence of competeing peptide versus the final concen­
tration of peptides.
T able II
Sum m ary o f the inhibition of the rate of factor X a  form ation and of 
factor V II coagulant activity by factor V II  synthetic peptides
Peptide
Cone for 50% inhibition”










° The rate of factor Xa formation was determined by amidolytic 
and coagulation assays as described under “Experimental Procedures” 
using varying concentrations of each of the inhibiting peptides. The 
concentration of each peptide which inhibited 50% of the rate of 
factor Xa formation or factor VII coagulant activity is indicated. The 
values were calculated relative to those measured in the absence of 
added peptide.
b ND, not determined.
Peptide Concentration (jiM )
Fig. 3. Dose-dependent inhibition of factor V II procoagu­
lant activity. Factor Vll-deficient plasma containing tissue factor 
was incubated with varying concentrations of peptides-(209-221) (•) , 
-(285-305) (■), and -(376-390) (A) for 30 min at 37 °C. The clotting 
time was measured after the addition of factor VII and calcium ions. 
The increase in clotting time relative to that in the absence of 
competing peptide is plotted against the peptide concentration.
is depicted in Fig. 3. All three peptides tested showed a dose- 
dependent increase in the clotting time. The CI5o values of 
these three peptides were much higher for factor X activation 
in the coagulation assay relative to their respective values in 
the purified protein system (Table II). The 5-10-fold higher 
CI50 value for the coagulation assay suggests that the peptides 
are more potent inhibitors of factor X  activation in a purified 
system. This may be because of the complexity of the coagu­
lation assay, which involves two additional reaction steps 
before reaching the end point, and also because of the presence 
of a higher concentration of factor VII. Furthermore, plasma- 
derived peptidases or nonspecific adsorption of peptides to 
plasma proteins may decrease the effective concentration of 
the synthetic peptides.
To characterize the type of inhibition, the rate of factor Xa 
formation was determined at different concentrations of fac­
tor X  while varying the concentration of synthetic peptides. 
Dixon plots of the data showing the ability of peptides to 
inhibit the rate of activation of factor X  are depicted in Fig.
4. Except for one peptide, the plot of inverse reaction rate 
versus the final concentration of peptide produced linear 
regression lines which intersected the abscissa, consistent 
with noncompetitive inhibition. In the case of peptide-(347- 
361), when the rate of factor Xa formation was determined at 
different concentrations of chromogenic substrate with vary­
ing peptide concentrations, the regression lines intersected at 
a point above the abscissa, indicating that the type of inhibi­
tion is competitive, which is consistent with its ability to 
inhibit factor Xa amidolytic activity. The peptide inhibition 
constants (K t) are summarized in Table III. Peptide-(285- 
305) was most inhibitory, with a K, value of 2.4 fiM. The Ki 
values were in the range of 42-65 jtM for peptides-(44-50), 
-(194-214), -(208-229), and -(376-390); and the least inhibi­
tory peptides were at positions 170-178 and 330-340, with K t 
values >200  ^M.
Finally, to demonstrate further that the inhibitory synthetic 
peptides represent important regions of factor VII which are 
responsible for its interaction with proteins involved in the 
factor X  activation complex, polyclonal antibodies were raised 
against four of these peptides. When antisera were assayed 
by a solid-phase radioimmunoassay, they bound not only to 
their respective immunizing peptides, but also to factor VII. 
The specific antibodies were purified by immunoaffinity chro- 
matograghy on factor Vll-agarose. Because the size of the 
factor VII-IgG complex is three times that of antigen alone, 
which may cause steric interference in the functional assay. 
Fab fragments (Mr =  50,000) of specific IgG were prepared 
and tested for their ability to inhibit the activation of factor 
X. The effect of varying concentrations of antipeptide Fab 
fragments on the rate of factor Xa formation is shown in Fig.
5. The Fab fragments specific for each of the four peptides 
inhibited the rates of factor Xa formation in a dose-dependent 
manner. The concentration which gives ~50% inhibition 
ranged from 8 to 25 pM, and the Fab fragment from the 
antibody raised against peptide-(285-305) was most inhibi­
tory. The fact that antibodies to these inhibitory peptides can 
react with factor VII supports the notion that the regions 
which these synthetic peptides represent on factor VII are 
largely surface-exposed and readily available to interact with 
tissue factor, factor X, or membrane surfaces, in addition to 
the antigen-binding sites of the Fab fragments.
DISCUSSION
Macromolecular assembly and protein substrate recogni­
tion are important aspects of the complex cascade pathway of 
blood coagulation. Factor VH-VIIa, in association with tissue
































Peptide Concentration ( (iM)
Fig. 4. Dixon plots o f inhibition of rate of activation of factor X  by factor V II synthetic peptides.
The indicated peptides a t varying concentrations were incubated with factor X at three different concentrations 
(4, 8 , and 12 nM) in the presence of tissue factor (0.075%). After the addition of factor VII (0.2 pM), the rate of 
factor X formation was determined. The inverse rate of factor Xa formation versus the final peptide concentrations 
is depicted. The point at which the regression lines converge on the abcissa was used to calculate the apparent 
inhibition constant (K,) for each peptide.
T able III
Peptide inhibition constants of factor V II synthetic peptides 
for factor X  activation
Peptide K,a
)lM
44-50 54.9 ±  7.2
170-178 215 ±  11.8
194-214 61.1 ±  4.7
208-229 44.3 ±  5.6
285-305 2.8 ±  0.4
330-340 247 ±  13.9
347-361 35.2 ±  6.2
376-390 57.8 ±  8.3
x
o
° Ki values were determined from Dixon plots of the rate of factor 
Xa formation and are expressed as the mean ±  S.D. for four to five 
determinations.
factor, is the first complex responsible for initiating blood 
coagulation through the extrinsic pathway. Factor VII shares 
a substantial degree of primary structural similarity (8) to 
other vitamin K-dependent serine proteases involved in blood 
coagulation, such as factors X  (40%) and IX (40%), prothrom­
bin (25%), and protein C (40%). Furthermore, a similar level 
of sequence similarity exists between the catalytic chain of 
coagulation serine proteases and digestive serine proteases 
such as trypsin and chymotrypsin (1, 26). Because this class 
of enzyme appears to have a common tertiary structure, it is 
reasonable to interpret the structure-function relationship of 
factor VII using a model based on the conformation of evo- 
lutionarily related enzymes (14-18). Sixteen synthetic pep­
tides of factor VII, corresponding to 55% of its primary 
structure, were employed in this study to identify the molec­
ular sites of interaction. The amino acid sequences of 13 of 
these peptides correspond to 80% of the catalytic chain,
Concentration of Fab ( nM )
FlG. 5. Inhibition of factor X a formation by antibodies 
raised against selected factor V II synthetic peptides. Rabbit 
antibodies raised against peptides-(44-50), (O), -(170-178) (■), -(208— 
229) (A), and -(285-305) ( • )  were affinity-purified on a factor VII- 
agarose column. The purified Fab fragments were preincubated with 
factor VII for 15 min at 37 °C. The rate of factor Xa formation 
relative to the rate observed in the presence of Fab fragments from 
nonimmune rabbit IgG is plotted versus the concentration of each 
antipeptide Fab fragment.
whereas one peptide composes sequences including the acti­
vation site, and two peptides represent 10 % of the light chain 
sequence.
The results presented here indicate that 7 of the 16 peptides 
have the ability to consistently prevent the factor VHa-tissue 
factor-mediated conversion of factor X  to factor Xa. Compe­
tition by these inhibitory peptides with factor VII for inter­
action with the factor X  activation complex was specific since 
no significant inhibition was observed with the other factor 
VII peptides. Five of the inhibitory synthetic peptides of factor 





























and -(376-390), are the most potent inhibitors when compared 
to the other two, peptides-(170-178) and -(330-340). Hence, 
the regions represented by the five most potent inhibitory 
peptides on factor VII may play a more direct role in the 
assembly of the factor X  activation complex. However, addi­
tional studies will be required to define the contribution of 
each individual residue within this region of factor VII. Dixon 
plots of all the peptides that inhibit the activation of factor 
X show a noncompetitive type of inhibition, indicating that 
the peptides do not directly interact with the active site of 
the activator.
It has been well established that antisera raised against 
small synthetic peptides are frequently capable of recognizing 
the native protein (27). Antibodies raised against each inhib­
itory peptide reacted selectively with the respective peptides 
and were affinity-purified on an factor VH-agarose column, 
indicating that the regions represented by these peptides are 
exposed and are available for interaction with other species 
at the solvent-accessible surface of factor VII. Amino acid 
residues of peptides-(44-50), -(208-229), and -(330-340) are 
predominantly hydrophilic, whereas the residues at positions 
285-305 are less so. Although a good correlation between 
hydrophilicity and surface accessibility has been reported (28) 
and both indices have been employed in identifying immu­
nogenic peptides (29, 30), not all parts of an epitope need 
adhere to these criteria. The inhibition of factor X  activation 
by antipeptide IgG Fab fragments further supports the notion 
that the regions on factor VII represented by these amino 
acid sequences are largely surface-exposed and mediate its 
interaction with other molecules, including antigen-binding 
sites on Fab fragments.
Among seven inhibitory peptides of factor VII, only peptide- 
(44-50) represents the amino acid sequence of the light chain, 
and the rest of them correspond to part of the heavy or 
catalytic chain sequence. The sequence of the light chain 
inhibitory peptide-(44-50) is located between the Gla domain 
and the second disulfide loop of the light chain. The tertiary 
structure of the Gla domain of prothrombin (31, 32) indicates 
that this region projects off the last turn of the a-helix of the 
Gla domain and may serve as a scaffold for anchoring a 
portion of its folded domain. In addition, this region on factors 
VII, X, and XI is extended by 5 residues and is predicted to 
be oriented toward the surface. Hence, it is reasonable to 
speculate that this amino acid sequence on the light chain 
may play a role in the membrane binding properties o f factor 
VII.
When the primary structures of the catalytic chains of 
different serine proteases are compared, small stretches of 
highly conserved sequences occur at various intervals along 
the polypeptide chain (33). Furie e t al. (16) identified seven 
conserved regions (CR) separated by six variable regions (VR) 
among the coagulation serine proteases. These conserved 
regions define the internal structure of the catalytic domains 
and active-site moieties of the serine proteases. The variable 
regions show little sequence similarity, involve short deletions 
and insertions, and are thought to be located on the surfaces 
of the proteins. These regions probably define the molecular 
surface and may be responsible for their diverse biological 
properties and selective enzymatic activity. The amino acid 
sequences of inhibitorypeptides-(170-178), -(196-214), -(208­
229), -(285-305), and -(330-340) are located in variable re­
gions VRj, VR2, VR3j VR4, and VR5 respectively, whereas 
peptide-(376-390) is in a conserved region (CR6). It appears 
that interactions with the factor X  activation complex may 
be mediated by as many as six regions on the solvent-exposed 
surface of the catalytic or heavy chain of factor VII. However,
when the primary structure of the catalytic chain was super­
imposed on the three-dimensional crystallographic structure 
of chymotrypsin (34, 35), these inhibitory peptide sequences 
were found to correspond to only three regions of chymotryp­
sin. The regions represented by peptides-(170-178), -(196— 
214), and -(208-229) are spatially close to one another and 
are located in the extended surface /3-loops which lie beyond 
the active site. Peptide-(285-305) forms a distinct loop located 
just above the active site. Finally, a region represented by 
peptides-(330-340) and -(376-390) is located directly beneath 
the extended substrate-binding pocket of chymotrypsin, 
which is lined by Ser214-Trp215-Gly216. The peptide backbone 
of these residues is thought to interact with the side chain of 
the substrate to properly orient the bond that is to be cleaved 
(36). Since peptides corresponding to these three regions, 
which are arranged spatially apart from one another on the 
surface of the molecule, inhibited factor X  activation, they 
could serve as specific molecular sites o f interaction with the 
components of the extrinsic pathway activation complex. In 
conclusion, the assembly and function of the extrinsic path­
way complex are mediated by at least four molecular loci on 
factor VII. However, identification of which region(s) on 
factor VII interact with complementary components such as 
tissue factor, factor X, and the membrane surface of the 
extrinsic pathway complex will require further investigation.
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